Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.67 |
| ▸ | TAF1 | P21675 | 7/20 | 0.67 |
| ▸ | PLK1 | P53350 | 12/20 | 0.64 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.64 |
| ▸ | BRDT | Q58F21 | 8/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | FES | P07332 | 2/20 | 0.59 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.59 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.59 |
| ▸ | CLK2 | P49760 | 2/20 | 0.59 |
| ▸ | NEK2 | P51955 | 2/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.59 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.59 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.59 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098806 | 1.00 | BRD4 (0.67) | BRD4TAF1PLK1MAPK7DYRK1A | |
| SCHEMBL619956 | 0.89 | PLK1 (0.69) | BRD4TAF1PLK1MAPK7DYRK1A | |
| SCHEMBL10098794 | 0.89 | PLK1 (0.69) | BRD4TAF1PLK1MAPK7DYRK1A | |
| SCHEMBL619179 | 0.86 | BRD4 (0.83) | BRD4TAF1PLK1MAPK7BRDT | |
| SCHEMBL10098776 | 0.86 | BRD4 (0.83) | BRD4TAF1PLK1MAPK7BRDT | |
| SCHEMBL21755685 | 0.86 | BRD4 (0.68) | BRD4TAF1PLK1MAPK7BRDT | |
| SCHEMBL21755686 | 0.84 | BRD4 (0.64) | BRD4TAF1PLK1MAPK7BRDT | |
| SCHEMBL3987399 | 0.82 | PLK1 (0.74) | BRD4TAF1PLK1BRDTALK | |
| SCHEMBL617429 | 0.81 | PLK1 (0.61) | BRD4TAF1PLK1MAPK7DYRK1A | |
| SCHEMBL10098784 | 0.81 | PLK1 (0.61) | BRD4TAF1PLK1MAPK7DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673144-A1 | CANCER THERAPY WITH TGF-BETA-2 AND IRINOTECAN AGENTS | GMP Biotechnology Limited (HK) | 2026-01-07 | — | — | EP | claimed |
| US-20250382619-A1 | CANCER THERAPY WITH TGF-BETA-2 AND IRINOTECAN AGENTS | GMP BIOTECHNOLOGY LTD (CN) | 2025-12-18 | — | — | US | claimed |
| WO-2025235822-A1 | THERAPEUTICS FOR CANCER USING TGFB2 AND TGM6 | GMP BIOTECHNOLOGY LIMITED (CN) | 2025-11-13 | — | — | WO | claimed |
| EP-4608452-A2 | PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Eisai R&D Management Co., Ltd. (JP) | 2025-09-03 | — | — | EP | claimed |
| US-20250270560-A1 | ANTI-CANCER AGENTS | GMP BIOTECHNOLOGY LTD (CN) | 2025-08-28 | — | — | US | claimed |
| WO-2024182585-A1 | CANCER THERAPY WITH TGF-BETA-2 AND IRINOTECAN AGENTS | GMP BIOTECHNOLOGY LIMITED (CN) | 2024-09-06 | — | — | WO | claimed |
| WO-2024092256-A2 | PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-02 | — | — | WO | claimed |
| CN-117897484-A | Antisense oligonucleotides and their use for treating neurodegenerative disorders | 卫材R&D管理有限公司 | 2024-04-16 | — | — | CN | claimed |
| EP-4330394-A2 | ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Eisai R&D Management Co., Ltd. (JP) | 2024-03-06 | — | — | EP | claimed |
| WO-2023049800-A1 | THERAPEUTICS FOR HAPLOINSUFFICIENCY CONDITIONS | Q-STATE BIOSCIENCES, INC. (US) | 2023-03-30 | — | — | WO | claimed |
| WO-2022232411-A2 | ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Eisai R&D Mangement Co., Ltd. (JP) | 2022-11-03 | — | — | WO | claimed |
| US-20180362545-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-20 | — | — | US | claimed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | claimed |
| EP-2379559-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute (US) | 2011-10-26 | — | — | EP | claimed |
| WO-2010120262-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MEDICAL CONDITIONS INVOLVING CELLULAR PROGRAMMING | SMITH HOLDINGS, LLC (US) | 2010-10-21 | — | — | WO | claimed |
| WO-2010080712-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-07-15 | — | — | WO | claimed |
| EP-4720299-A1 | TGFB2-IRF5 THERAPEUTICS FOR CANCER | GMP Biotechnology Limited (HK) | 2026-04-08 | — | — | EP | disclosed |
| US-20250382619-A1 | CANCER THERAPY WITH TGF-BETA-2 AND IRINOTECAN AGENTS | GMP BIOTECHNOLOGY LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382619-A1 | CANCER THERAPY WITH TGF-BETA-2 AND IRINOTECAN AGENTS | FOLR2, TGFB2, TGFBR2 | BRD4 4776/4885TAF1 3987/4885PLK1 1798/4885 |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | BRD4 555/4885TAF1 1732/4885PLK1 109/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | BRD4 614/4885TAF1 1629/4885PLK1 110/4885 |
| US-20180362545-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | BRD4 614/4885TAF1 1629/4885PLK1 110/4885 |
| US-20250270560-A1 | ANTI-CANCER AGENTS | ITGB5, ITGA5, ITGAM | BRD4 958/4885TAF1 1575/4885PLK1 2190/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | BRD4 396/4885TAF1 2788/4885PLK1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.